Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479252 | 0.86 | PDE4A (0.35) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25332384 | 0.86 | PDE4A (0.35) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25967134 | 0.83 | PDE4A (0.34) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21947679 | 0.82 | CCNC (0.47) | PDE10AMEN1KMT2AKDM4EHTT | |
| SCHEMBL25953862 | 0.81 | PDE4A (0.33) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25334284 | 0.75 | ESR1 (0.40) | ESR1KMT2AKDM4EESR2 | |
| SCHEMBL30479233 | 0.75 | ESR1 (0.40) | ESR1KMT2AKDM4EESR2 | |
| SCHEMBL25952570 | 0.74 | ESR1 (0.41) | ESR1KMT2AKDM4EESR2 | |
| SCHEMBL30479230 | 0.74 | ESR1 (0.48) | ESR1VNN1 | |
| SCHEMBL23355223 | 0.74 | ESR1 (0.48) | ESR1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472982-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12128040-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-10-29 | — | — | US | disclosed |
| CN-118647619-A | Process for preparing selective estrogen receptor degrading agent | 伊莱利利公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240199629-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2024-06-20 | — | — | US | disclosed |
| US-11993608-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-05-28 | — | — | US | disclosed |
| US-11926634-B2 | Processes for the preparation of selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4308581-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117379428-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-112424205-B | Selective estrogen receptor degrading agents | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116981679-A | Selective estrogen receptor degrading agent | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11117902-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117902-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3820874-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3820873-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112638916-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112424205-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200347073-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2020-11-05 | — | — | US | disclosed |
| US-20200347073-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2020-11-05 | — | — | US | disclosed |
| US-10654866-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654866-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199629-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESRRA | ESR1 1/4885PDE4A 1963/4885PDE4B 2554/4885 |
| US-11993608-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885PDE4A 2989/4885PDE4B 3594/4885 |
| US-20200347073-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885PDE4A 2989/4885PDE4B 3594/4885 |
| US-11117902-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885PDE4A 2989/4885PDE4B 3594/4885 |
| US-11926634-B2 | Processes for the preparation of selective estrogen receptor degraders | ESR1, GPER1, ESRRA | ESR1 1/4885PDE4A 1963/4885PDE4B 2554/4885 |
| US-12128040-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885PDE4A 3324/4885PDE4B 3797/4885 |
| US-10654866-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885PDE4A 2989/4885PDE4B 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.